12 12, 2017

Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients

2018-01-16T10:09:25+00:00December 12th, 2017|

London, Paris and Boston, 12 December 2017: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment. […]

4 11, 2017

CTAD 2017 (Boston, USA | 1-4 Nov)

2017-11-07T13:11:30+00:00November 4th, 2017|

Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. […]

12 10, 2017

Anavex incorporating Ariana’s KEM® AI platform in Alzheimer’s precision medicine approach

2017-10-18T11:38:59+00:00October 12th, 2017|

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients ANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed. Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success in forthcoming Phase 2/3 study. NEW YORK, October 12, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL) today announced pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in mild-to-moderate Alzheimer’s disease patients. ANAVEX2-73 targets the sigma-1 receptor, which regulates neuroplasticity and cellular homeostasis. [...]

26 06, 2017

WIN 2017 (Paris | Jun 26-27)

2017-06-26T10:48:45+00:00June 26th, 2017|

Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. […]

16 05, 2017

API 2017 (Panama | May 16-20)

2017-05-16T20:31:42+00:00May 16th, 2017|

Two posters highlighting the use of Ariana’s Real World Evidence (RWE) platform for large scale data mining of healthcare records are to be presented at API 2017 (Asociacion Panamericana de Infectologia) – XVIII Congresso Panamericano de Infectologia, Panama, 16-20 May 2017. […]

5 10, 2016

Anavex and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs

2016-10-05T13:37:50+00:00October 5th, 2016|

NEW YORK, NY – October 5, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced a collaboration with Ariana Pharma (Cambridge, MA and Paris, France) to use Ariana’s proprietary KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73’s Phase 2/3 Alzheimer’s clinical development timelines. KEM® is a comprehensive and FDA-tested clinical data analysis system that enables full exploitation of complex datasets including of smaller numbers of patients. [...]

Load More Posts